Harmony Biosciences Raises $270m; Acquires US Rights To Narcolepsy Drug
Emerging US biotech Harmony Biosciences has secured $270m in financing to acquire a Phase III narcolepsy drug, which it expects to file with the FDA in 2018.
You may also be interested in...
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The latest drug development news and highlights from our US FDA Performance Tracker.
Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.